低中收入国家环境下磁共振引导自适应近距离放疗治疗局部晚期宫颈癌的经验
在低中收入国家三级癌症中心的前瞻性EMBRACE方案中,94例局部晚期宫颈癌(II/III期)患者接受外照射(45 Gy/25次,±每周顺铂)后行磁共振引导自适应近距离放疗(4次×7 Gy)。中位随访39个月,局部控制率90.1%±3.4%,无进展生存率72.1%±4.8%,3级膀胱毒性和直肠毒性分别为3%和9%。
要点
- 磁共振引导自适应近距离放疗在低中收入国家可行,局部控制率与无进展生存率良好。
- 局部失败仅见于IIIB期,且与近距离放疗时更大的高危临床靶体积相关。
- 3级晚期膀胱毒性和直肠毒性发生率分别为3%和9%。
核心结论
- 磁共振引导自适应近距离放疗可显著改善局部晚期宫颈癌的局部控制率和无进展生存率,值得在发展中国家推广。
研究设计与样本
- 前瞻性EMBRACE方案纳入94例局部晚期宫颈癌(II/III期)患者,来自低中收入国家三级癌症中心。
- 外照射45 Gy/25次(±每周顺铂)后行磁共振引导自适应近距离放疗4次×7 Gy。
主要发现
- 近距离放疗第一次和第二次的高危临床靶体积均值分别为46.94±24.6 cm³和42.7±22.5 cm³。
- 高危临床靶体积D90均值为88.3±4.4 GyEQD2。
- 中位随访39个月,局部控制率为90.1%±3.4%,无进展生存率为72.1%±4.8%。
- 3级膀胱毒性和直肠毒性发生率分别为3%和9%。
- 39个月局部控制率在IIB和IVA期患者中显著优于IIIB期(100% vs 85%,P=.013)。
关键数值与推荐
- 局部失败仅见于IIIB期,且局部失败患者近距离放疗时高危临床靶体积显著更大(70±25.7 cm³ vs 44.3±21.9 cm³,P=.01)。
- 局部失败与高危临床靶体积D90无关(86.3±3.9 Gy10 vs 88.5±5 Gy10,P=.987)。
临床怎么用
- 在低中收入国家可考虑推广磁共振引导自适应近距离放疗以改善局部晚期宫颈癌疗效。
- 对IIIB期及高危临床靶体积较大的患者需关注局部失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the clinical impact of magnetic resonance image guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer (LACC) (stages II and III) in a tertiary care cancer hospital in a low and middle income countries setting. METHODS AND MATERIALS: Ninety-four LACC patients enrolled in a prospective EMBRACE (An International Study on MRI-Guided Brachytherapy in Locally Advanced Cervical Cancer) protocol treated with external radiation therapy (45 Gy in 25 fractions) with or without weekly cisplatin, followed by magnetic resonance IGABT (4 fractions of 7 Gy), were analyzed in detail for dosimetric and clinical outcomes including late toxicities. RESULTS: The mean (± standard deviation) high-risk clinical target volume (HR-CTV) at the first session of brachytherapy and at the second session of brachytherapy for the current study cohort was 46.94 ± 24.6 cm3 and 42.7 ± 22.5 cm3, respectively, with mean minimum dose received by 90% volume (D90) of 88.3 ± 4.4 equivalent 2-Gy fractionation (GyEQD2). At median follow-up (39 months), the local control rate (LCR) and overall progression-free survival rate were 90.1% ± 3.4% and 72.1% ± 4.8%, respectively, with grade 3 bladder toxicity in 3% of patients and rectum toxicity in 9%. The LCR at 39 months was significantly better in patients with stage IIB and IVA disease versus stage IIIB disease (100% vs 85%, P=.013). Local failures were limited to stage IIIB only and were associated with significantly larger HR-CTVs at brachytherapy (70 ± 25.7 cm3 vs 44.3 ± 21.9 cm3, P=.01) but not with HR-CTV D90 doses (which were similar for patients who had local failures vs those who did not: 86.3 ± 3.9 α/β equal to 10 Gy (Gy10) vs 88.5 ± 5 α/β equal to 10 Gy, P=.987). CONCLUSIONS: IGABT leads to a significant improvement in LCR and overall progression-free survival in LACC and should be considered for wider implementation in developing countries to improve outcomes.
引用
- Mahantshetty U, Krishnatry R, Hande V, et al. Magnetic Resonance Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: An Experience From a Tertiary Cancer Center in a Low and Middle Income Countries Setting. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280456. doi:10.1016/j.ijrobp.2017.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。